Status:
COMPLETED
Breathomics: May it Become an Affordable, New Tool for Early Diagnosis and Screening of Lung Cancer?
Lead Sponsor:
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Collaborating Sponsors:
University of Michigan
Humanitas Hospital, Italy
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Breath analysis examining specific patterns of volatile organic compounds (VOCs) has been demonstrated to be able to discriminate lung cancer (LC) patients from healthy controls (HC). However, the exi...
Detailed Description
The breath of patients with histologically proven NSCLC and healthy controls was sampled into Tedlar bags through a Nafion filter and a one-way mouthpiece. The breath samples in the bags were then ana...
Eligibility Criteria
Inclusion
- NSCLC histologically proven (for LC group) at any stage of disease
- non-cancer controls who had negative findings on preoperative chest X-rays/chest CT scan (for HC groups)
Exclusion
- Patients who had any history of another type of cancer
- who had received neoadjuvant chemo/radiotherapy because of the possible unknown effects on cancer metabolism
- pediatric patients.
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06034730
Start Date
April 1 2021
End Date
August 1 2023
Last Update
September 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda Consorziale Ospedaliero-Universitaria Policlinico di Bari - Thoracic Surgery Unit
Bari, Italy, 70121